New Data on Paxlovid Reported

Abstract

According to this study: In a phase 2/phase 3 study of Paxlovid use in patients at standard risk for developing severe COVID-19, the primary end point of self-reported sustained alleviation of all symptoms for four consecutive days wasn't met.A nonsignificant risk reduction in hospitalizations and death was seen in a subgroup of patients who had at least one risk factor for severe COVID-19.